This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Ultrapure Water System for Hemodialysis Therapy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2010 by Tel Aviv Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by:
Tel Aviv Medical Center Identifier:
First received: July 21, 2011
Last updated: NA
Last verified: November 2010
History: No changes posted
We wish to compare the effect of very clean water used for dialysis therapy (i.e ultrapure water) in comparison with the use of conventional water which are used in most dialysis units worldwide. To the best of our knowledge prospective data in that field is sparse.

The Change of Biomarkers CRP, CBC With the Use of Ultra Pure Water System for Hemodialysis. The Rate of Adverse Events Such as Hypotension During Hemodialysis Therapy With Ultra Pure Water System as Compared to Conventional Water System.

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Effect of Ultrapure Water System on Hemodialysis Therapy- a Single Center Trial

Resource links provided by NLM:

Further study details as provided by Tel Aviv Medical Center:

Primary Outcome Measures:
  • CRP [ Time Frame: 13 months ]

Secondary Outcome Measures:
  • blood pressure [ Time Frame: 13 months ]

Estimated Enrollment: 150
Study Start Date: August 2011
Estimated Study Completion Date: January 2013
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Detailed Description:
In observational studies, the use of very pure dialysis solution has been suggested to reduce the plasma level of CRP, IL-6 ; to improve the response to anemia to erythropoietin therapy ; to promote better nutrition as evidenced by increase in plasma albumin value , estimated dry body weight, midarm muscle circumference and urea-nitrogen appearance rate; to reduce plasma level of β2-microglobulin and pentosidine ; to dely carpal tunnel syndrome ; to slow the loss of residual renal function; and to lower cardiovascular morbidity.The aim of this study is to prospectively evaluate the effect of dialysis performed with ultra-pure water (UPW)in comparison with dialysis with the use of conventional water system. Patients enrolled into this study will be evaluated at initial period of one month treated with conventional water system (-30 to 0 days). Then water system will be switched to ultra-pure water system with the use of filter added to the dialysis machine (Gambro). After switching to UPW system the patients will be followed for a period of one year (days 0-365). Primary end point will be change in CRP. Additional parameters: Blood pressure, adverse events during dialysis, hemoglobin levels and white-blood cell counts.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Chronic hemodialysis patients

Inclusion Criteria:

  1. chronic hemodialysis therapy thrice weekly > 3 months of therapy
  2. Signed an informed consent -

Exclusion Criteria:

  1. Enrolled to other study
  2. Ongoing infection -
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01400126

Contact: Doron Schwartz, MD
Contact: Gil Chernin, MD

Sponsors and Collaborators
Tel Aviv Medical Center
  More Information

Responsible Party: Prof. Doron Schwartz, TelAvivMC Identifier: NCT01400126     History of Changes
Other Study ID Numbers: 01
Study First Received: July 21, 2011
Last Updated: July 21, 2011

Keywords provided by Tel Aviv Medical Center:
Ultrapure water,hemodialysis, CRP, blood pressure

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases processed this record on September 21, 2017